Cardiac arrest & resuscitation
Cytokine hemoadsorption with CytoSorb® in post-cardiac arrest syndrome, a pilot randomized controlled trial
Authors' conclusion
In CA survivors at risk of PCAS, HA was feasible, safe and was associated with a nonsignificant reduction in cytokine plasma levels.
Study context
- Population
- ICU patients after cardiac arrest (CA) at risk of post-cardiac arrest syndrome (PCAS) (norepinephrine > 0.2 µg/kg/min, and/or lactate > 6 mmol/l and/or time-to-ROSC > 25 min); ECMO or RRT excluded16 (76%) OHCA
- Participants
- 21 patients
- Comparison
- Standard of care (SOC) plus hemoadsorption (HA) with CytoSorb® vs SOC
- HAn = 10
- SOCn = 11reference
Methodological detailspilot
- Pilot
Primary result
As reported in the abstract
Relative reduction in IL-6 at 48 h · 48 h
HA
75%
median · IQR 60–94
SOC
5%
median · IQR - 47, 70
P = 0.06
Further findings
- Feasibility of HA
- 21 · median · IQR 14–24 · h
Feasibility of HA
- HA initiated in all patients allocated to HA
Safety
aPTT elevation
- Trend for higher rate of aPTT elevation with the intervention: 5 (50%) vs 2 (18%)
- P = 0.18
- Intervention otherwise well tolerated
Mild thrombocytopenia (100-150 G/L) · day 1
- Trend for higher rate of mild thrombocytopenia with the intervention: 5 (50%) vs 2 (18%)
- P = 0.18
Original publication
Cytokine hemoadsorption with CytoSorb® in post-cardiac arrest syndrome, a pilot randomized controlled trial. Crit Care. Published 23 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →